Abstracts

237 – Assessing Susceptibility of Cervical Explant Tissue of Transgender Men to HIV-1 Infection

Background HIV-1 disproportionately affects minority groups, including transgender individuals, in the USA. Masculinizing hormonal therapy, integral to gender-affirming care for transgender men (TGM), has immunomodulatory properties that heighten HIV-1 acquisition risk. Testosterone activates both myeloid and lymphoid cells through androgen receptors (ARs), resulting in a shift in the cytokine milieu and a defective innate immune…

793 – Broadly Neutralizing Antibodies in Oral Secretion After Administration to Newborns Exposed to HIV

Background Broadly neutralizing antibodies (bNAbs) hold promise for HIV perinatal prophylaxis. Three anti-CD4 binding site bNAbs, VRC01, VRC01LS (longer plasma half-life), and VRC07-523LS (greater potency, longer plasma half-life), have favorable plasma pharmacokinetics (PK) when administered subcutaneously (SC) to newborns exposed to HIV. Concentrations of bNAbs in oral secretions (OS) may be relevant to protection from…

809 – Determinants of PrEP Discontinuation in Pregnant and Breastfeeding Women: Lower Eastern Kenya, 2023

Background  HIV incidence rates amongst pregnant and breastfeeding women (PBFW) in sub-Saharan Africa are 5.9 and 3.4 per 100 person-years, above the WHO’s risk threshold of ≥3.0. The vertical transmission of HIV (VTH) in Kenya is 9.3%. However, lower Eastern counties of Machakos, Kitui, and Makueni have significantly higher VTH than the national average yet factors…

1033 – Acceptability of the Meningococcal Group B Vaccine to Prevent Gonorrhea Among South African Women

Background Women in eastern and southern Africa experience high rates of Neisseria gonorrheae (NG). NG treatments are limited with increasing antimicrobial resistance. Observational data indicate potential partial protection against NG with the 4CMenB (Bexsero) vaccine. Future vaccine uptake however will depend in part on its acceptability in target populations. Methods BIYELA is a randomized, double-blind…

841 – Viremia Accelerates VRC01 Clearance in Infants Living With HIV-1: Insights From IMPAACT 2008

Background VRC01, a CD4 binding–site broadly neutralizing antibody (bNAb), was administered concomitantly during the initiation of early antiretroviral treatment (ART) in infants with HIV-1 in IMPAACT 2008. We characterized VRC01 population pharmacokinetics (PopPK) and explored clinical factors associated with VRC01 PopPK. Methods Twenty-nine infants (median age at entry 2.4 months, range 1.6-2.8 months) received VRC01…

323 – Kinetics of Humoral and Cellular Immunity up to 3 Years After MVA-BN Vaccination

Background The ongoing mpox epidemic and the limited vaccine supply have raised concerns about the long-term effectiveness of the primary MVA-BN vaccination schedule. We evaluated humoral and T-cell immune responses up to three years after MVA-BN vaccination, according to prior smallpox immunisation. Methods Blood samples from individuals receiving a primary MVA-BN cycle (two doses for…

329 – Longitudinal Immune-Virologic Study of HIV Exceptional Elite Controllers With Distinct Outcomes

Background  HIV-1 exceptional elite controllers (EECs) represent a model of functional cure, able to sustain undetectable viremia and prevent disease progression for decades without therapy. After 35 years of follow-up, we describe two EECs who lost viral control (transient controllers, T-EEC) and compare them with two persistent controllers (P-EEC) who maintained long-term remission. These cases…

623 – Ten-Year Cancer Survival Rate in an Italian Cohort of People With HIV From 2008 to 2025

Background People with HIV (PWH) are at increased risk of developing malignancies. This study aimed to estimate long term survival rates in PWH diagnosed with cancer, stratified by virus-related cancer (VRC; anal and invasive cervical cancer, hepatocellular carcinoma, Kaposi sarcoma, Hodgkin and non-Hodgkin lymphoma) and non–virus-related cancer (NVRC).  Methods We included PWH with a VRC…

625 – Kaposi Sarcoma, With and Without Pulmonary Involvement: Clinical Differences and Outcomes

Background Kaposi sarcoma (KS) is caused by human herpes 8 virus (HHV8); immunosuppression and inflammatory cytokines play a major role in its pathogenesis. We aimed to describe the clinical differences and outcomes of patients with disseminated KS, with and without pulmonary involvement. Methods We conducted a single-center retrospective cohort study from 2018 to 2024, including…